Current Status and Future Directions in Gastric Cancer with Peritoneal Dissemination

Surgical Oncology Clinics of North America

Volumn 21, Issue 4, 2012, Pages 625-633

  Glockzin, Gabriel ^a   Piso, Pompiliu ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Saint John of God Hospital Regensburg   (Germany)

Author keywords

Cytoreductive surgery; Gastric cancer; HIPEC; Peritoneal carcinomatosis; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; TRASTUZUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; HYPERTHERMIC THERAPY; PATIENT SELECTION; PERITONEUM METASTASIS; POSTOPERATIVE COMPLICATION; REVIEW; STOMACH CANCER; SURVIVAL RATE; TREATMENT INDICATION; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; HYPERTHERMIA, INDUCED; PATIENT SELECTION; PERITONEAL NEOPLASMS; PERITONEUM; PREOPERATIVE CARE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84866789451     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2012.07.002     Document Type: Review

References (40)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Ikeguchi M., Oka A., Tsujitani S., et al. Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer. Anticancer Res 1994, 14:2131-2134.
3. D'Angelica M., Gonen M., Brennan M.F., et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004, 240:808-816.
4. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008, 359:453-462.
5. Sadeghi B., Arvieux C., Glehen O., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88:358-363.
6. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8:163-168.
7. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909.
8. Pyrhonen S., Kuitunen T., Nyandoto P., et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71:587-591.
9. Murad A.M., Santiago F.F., Petroianu A., et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72:37-41.
10. Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15:261-267.
11. Ajani J.A., Moiseyenko V.M., Tjulandin S., et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007, 25:3205-3209.
12. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
13. Ceelen W.P., Bracke M.E. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 2009, 10:72-79.
14. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002, 20:1996-2004.
15. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
16. Glockzin G., Schlitt H.J., Piso P. Peritoneal carcinomatosis: patient selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2009, 7:5.
17. Ceelen W.P., Flessner M.F. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 2010, 7:108-115.
18. Sugarbaker P.H. Peritonectomy procedures. Ann Surg 1995, 221:29-42.
19. Gonzalez-Moreno S., Gonzalez-Bayon L.A., Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2010, 2:68-75.
20. Yan T.D., Black D., Sugarbaker P.H., et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 2007, 14:2702-2713.
21. Kuramoto M., Shimada S., Ikeshima S., et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009, 250:242-246.
22. Glehen O., Gilly F.N., Arvieux C., et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010, 17:2370-2377.
23. Yang X.J., Huang C.Q., Suo T., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011, 18:1575-1581.
24. Jacquet P., Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996, 82:359-374.
25. Glehen O., Gilly F.N. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003, 12:649-671.
26. Esquivel J., Chua T.C. CT versus intraoperative peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: importance of the difference between statistical significance and clinical relevance. Ann Surg Oncol 2009, 16(9):2662-2663.
27. Fujimoto S., Takahashi M., Mutou T., et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997, 79:884-891.
28. Loggie B.W., Fleming R.A., McQuellon R.P., et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000, 66:561-568.
29. Hall J.J., Loggie B.W., Shen P., et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004, 8:454-463.
30. Glehen O., Schreiber V., Cotte E., et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004, 139:20-26.
31. Yonemura Y., Kawamura T., Bandou E., et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005, 92:370-375.
32. Gill R.S., Al-Adra D.P., Nagendran J., et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011, 104:692-698.
33. Cheong J.H., Shen J.Y., Song C.S., et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol 2007, 14:61-68.
34. Yang X.J., Li Y., Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol 2010, 101:457-464.
35. Glehen O., Gilly F.N., Boutitie F., et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer 2010, 116:5608-5618.
36. Shen P., Stewart J.H., Levine E.A. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: non-colorectal indications. Curr Probl Cancer 2009, 33:168-193.
37. Piso P., Slowik P., Popp F., et al. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2009, 16:2188-2194.
38. Sugarbaker P.H. Cytoreduction including total gastrectomy for pseudomyxoma peritonei. Br J Surg 2002, 89:208-212.
39. Kusamura S., Younan R., Baratti D., et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006, 106:1144-1153.
40. Levine E.A., Stewart J.H., Russell G.B., et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg 2007, 204:943-953. [discussion: 53-5].